Clinical trial
Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected…
NCT00270465 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00270465 |
|---|---|
| Title | Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients |
| Official title | VRC101: A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost HIV-1 Vaccination Schedule of a 6-Plasmid Multiclade HIV-1 DNA Vaccine, VRC-HIVDNA016-00-VP, Followed by a Recombinant Multiclade Adenoviral Vector HIV Vaccine |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV |
| Intervention type | Drug |
| Interventions | VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP |
| Enrollment | 17 |
| Start date | Dec 21, 2005 |
| Primary completion | Jun 25, 2009 |
| Completion | Jun 25, 2009 |
| First posted | Dec 26, 2005 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: